ZURA (Zura Bio) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Days Payable?

Zura Bio's average Accounts Payable for the three months ended in Dec. 2024 was $0.87 Mil. Zura Bio's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Zura Bio's Days Payable or its related term are showing as below:

ZURA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.62
* Ranked among companies with meaningful Days Payable only.

Zura Bio's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Zura Bio Days Payable Historical Data

The historical data trend for Zura Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Days Payable Chart

Zura Bio Annual Data

Trend

Mar22

Dec23

Dec24

Days Payable

Zura Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Zura Bio's Days Payable

For the Biotechnology subindustry, Zura Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zura Bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Zura Bio's Days Payable falls into.

Save Embed

;

Save Embed

;

Zura Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Zura Bio's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (2.749	+	0.733)	/	2 )	/	0	*	365
=	1.741					/	0	*	365
=	N/A

Zura Bio's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (1.014	+	0.733)	/	2 )	/	0	*	365 / 4
=	0.8735					/	0	*	365 / 4
=	N/A

Zura Bio Days Payable Related Terms

Thank you for viewing the detailed overview of Zura Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014

Website

https://www.zurabio.com

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Executives

Parvinder Thiara	director, 10 percent owner	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Someit Sidhu	director	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Ploos Van Amstel Arnout	director	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Amit Munshi	director	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Michael Howell	officer: SVP, Translational Medicine	4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Ewon Comfortech Co., Ltd.	10 percent owner	8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Chris Kim	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Hana Immunotherapeutics Llc	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Theresa Lowry	officer: EVP and CHRO	3629 VILLA TERRACE, SAN DIEGO CA 92104
Gary Whale	officer: EVP and CTO	2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Kimberly Ann Davis	officer: Secretary and General Counsel	C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni	director	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192